Clinical trials: Myocardial Infarct
Cost Sharing, Acute Coronary Syndrome
Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study
Current patterns of P2Y12 receptor inhibitor use provide an excellent opportunity to test the impact of copayment reduction on clinician choice of medication, patient adherence, and clinical outcomes.
- Trial name
- ARTEMIS (NCT02406677)
- Testing
- Study voucher card
- Where
- 272 sites in United States, Puerto Rico
- Volunteers
- 11,001 people
- Sponsor
- AstraZeneca
End Stage Renal Disease Requiring Hemodialysis
Factor XI LICA to Reduce Events Such as Heart Attack and Stroke in Patients Whose Kidneys Are no Longer Able to Work as They Should and Require Treatment to Filter Wastes From the Blood: Focus is on the Safety of BAY2976217 and the Way the Body Absorbs, Distributes and Removes the Study Drug
Patients whose kidneys are no longer able to work as they should and require treatment to filter wastes from the blood (hemodialysis) are at high risk for blood clots that form in blood vessels (thrombosis) blocking blood flow…
- Trial name
- RE-THINc ESRD (NCT04534114)
- Testing
- Fesomersen sodium (BAY2976217)
- Where
- 69 sites in United States, Belgium and 13 more
- Volunteers
- 307 people
- Sponsor
- Bayer
Myocardial Infarction, Arthritis
Mechanisms of Action of Acetaminophen
This research study investigates whether the ability of aspirin to reduce the risk of heart attacks may be diminished by the administration of acetaminophen.
- Trial name
- NCT00646906
- Testing
- Aspirin First, Aspirin Last, Acetaminophen 1000 mg/d
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Shock, Cardiogenic, High Risk Percutaneous Coronary Interventions
Synchronized Cardiac Assist for Cardiogenic Shock
The purpose of this study is to collect prospective safety and performance information for the i-COR® device using synchronized cardiac assist in the setting of combined heart-lung failure or in high risk percutaneous…
- Trial name
- NCT02697006
- Testing
- i-cor Synchronized Cardiac Assist Device
- Where
- Germany
- Volunteers
- 47 people
- Sponsor
- Xenios AG
Chronic Ischemic Left Ventricular Dysfunction, Myocardial Infarction
The TRansendocardial Stem Cell Injection Delivery Effects on Neomyogenesis STudy (The TRIDENT Study)
Thirty (30) patients with chronic ischemic left ventricular dysfunction secondary to MI scheduled to undergo cardiac catheterization will be enrolled in the study.
- Trial name
- Trident (NCT02013674)
- Testing
- Allogeneic hMSCs
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Joshua M Hare
Diabetes Mellitus, Type 2
A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to compare the effect of ticagrelor versus placebo in patients with Type 2 Diabetes Mellitus.
- Trial name
- THEMIS (NCT01991795)
- Testing
- Ticagrelor 60 mg
- Where
- 1,237 sites in United States, Argentina and 41 more
- Volunteers
- 19,271 people
- Sponsor
- AstraZeneca
ST Elevation Myocardial Infarction
A Study to Evaluate the Safety and Efficacy of MEDI6012 in Acute ST Elevation Myocardial Infarction
This is a Phase 2b randomized, blinded, placebo controlled study to evaluate the efficacy, safety, PK/pharmacodynamic, and immunogenicity of repeat doses of MEDI6012 in adult participants presenting with acute STEMI (ST segment…
- Trial name
- REAL-TIMI 63B (NCT03578809)
- Testing
- MEDI6012
- Where
- 37 sites in Brazil, Czechia and 8 more
- Volunteers
- 593 people
- Sponsor
- MedImmune LLC
Acute Myocardial Infarction, STEMI
A Study of Acute Myocardial Infarction Using FDY-5301
The purpose of this study is to evaluate the safety, efficacy, and pharmacokinetics (PK) of three dose levels of FDY-5301 compared to placebo in STEMI patients undergoing PCI.
- Trial name
- NCT03470441
- Testing
- FDY-5301
- Where
- 23 sites in United States, Hungary and 2 more
- Volunteers
- 120 people
- Sponsor
- Faraday Pharmaceuticals, Inc.
Systemic Arterial Hypertension, Hypertension Resistant to Conventional Therapy
Renin-angiotensin-aldosterone System Polymorphisms in Resistant Hypertension and Adverse Cardiovascular Events
Renin-angiotensin-aldosterone system (RAAS) polymorphisms influence 24h arterial pressure fluctuation. Resistant systemic arterial hypertension (RSAH) has an increased risk of end organ damage and unfavourable prognosis, whereas…
- Conditions
- Systemic Arterial Hypertension, Hypertension Resistant to Conventional Therapy, Myocardial Infarction, Stroke
- Trial name
- GENHART (NCT01173029)
- Testing
- Anti-hypertensive drug treatment
- Where
- Brazil
- Volunteers
- 92 people
- Sponsor
- Universidade Gama Filho
Myocardial Infarction, Ischemic Heart Disease
Half-Dose Radiopharmaceutical in Wide Beam Reconstruction
This study is recruiting patients already scheduled for a single photon emission computed tomography myocardial perfusion imaging (SPECT-MPI) test.
- Trial name
- REGA-1102 (NCT01499654)
- Testing
- Half-dose of the Tc99-m sestamibi (Cardiolite)
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Edwin Wu
Acute Myocardial Infarction
Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI
The purpose of this study is to evaluate the efficacy and safety of LCZ696 titrated to a target dose of 200 mg twice daily, compared to ramipril titrated to a target dose of 5 mg twice daily.
- Trial name
- PARADISE-MI (NCT02924727)
- Testing
- LCZ696 (sacubitril/valsartan), Ramipril, Valsartan
- Where
- 486 sites in United States, Argentina and 39 more
- Volunteers
- 5,669 people
- Sponsor
- Novartis Pharmaceuticals
Coronary Artery Bypass, Myocardial Ischemia
Glutamate for Metabolic Intervention in Coronary Surgery
The main purpose of this study is to determine whether intravenous glutamate infusion given in association with surgery for unstable coronary artery disease can protect the heart from myocardial injury, postoperative heart…
- Conditions
- Coronary Artery Bypass, Myocardial Ischemia, Myocardial Infarction, Coronary Artery Disease
- Trial name
- GLUTAMICS (NCT00489827)
- Testing
- Intravenous infusion of saline, Intravenous glutamate infusion
- Where
- 3 sites in Sweden
- Volunteers
- 865 people
- Sponsor
- University Hospital, Linkoeping
Peripheral Artery Disease
A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease
The purpose of this study is to compare the effects of ticagrelor and clopidogrel in patients with Peripheral Artery Disease.
- Trial name
- EUCLID (NCT01732822)
- Testing
- Ticagrelor, Clopidogrel
- Where
- 776 sites in United States, Argentina and 26 more
- Volunteers
- 13,885 people
- Sponsor
- AstraZeneca
Heart Disease
Vet-Harts Pilot Intervention for Veterans With Coronary Heart Disease
The purpose of this research study is to survey patients to learn about their beliefs and behaviors related to the management of heart disease and to discuss options for making healthy lifestyle changes.
- Trial name
- VHPI (NCT01566214)
- Testing
- Motivational Interview
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- VA Office of Research and Development
Cardiovascular Diseases, Cardiovascular Abnormalities
The Effects of the Dietary Supplement CardioFlex Q10 on Reducing Cardiovascular Disease Risk Factors in Adults
Cardiovascular diseases (CVD), primarily heart disease and stroke, are the leading causes of death and prescription drug use in Canada.
- Conditions
- Cardiovascular Diseases, Cardiovascular Abnormalities, Heart Attack, Stroke
- Trial name
- NCT03826914
- Testing
- CardioFlex Q10
- Where
- Canada
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- University of Manitoba
Atherosclerosis
Aliskiren Effect on Aortic Plaque Progression
This study is being done to assess the effectiveness of short term (~9 months) Aliskiren/Placebo therapy to slow down the progression of atherosclerotic disease in thoracic and abdominal aorta.
- Trial name
- ALPINE (NCT01417104)
- Testing
- Aliskiren
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- Ohio State University
Myocardial Infarction, No-Reflow Phenomenon
Genetic Determinants of the Coronary Microvascular Obstruction in PCI
Myocardial infarction (MI) remains one of the most common causes of death. Percutaneous coronary intervention (PCI) is the main treatment option to restore blood flow through the infarction-related coronary artery (IRA) in MI…
- Trial name
- NCT05355532
- Testing
- different variants of SNPs that may be associated with the coronary microvascular obstruction development
- Where
- 2 sites in Russia
- Volunteers
- 80 people
- Sponsor
- Privolzhsky Research Medical University
Post Acute Coronary Syndrome, Myocardial Ischemia
Efficacy and Safety of Aliskiren and Valsartan Versus Placebo in Patients Stabilized Following an Acute Coronary Syndrome
The purpose of this study is to test the hypothesis that the inhibition of the renin-angiotensin-aldosterone system (RAAS) with the angiotensin receptor blocker valsartan or the renin antagonist aliskiren will improve ventricular…
- Trial name
- NCT00409578
- Testing
- Aliskiren 300 mg, Valsartan 320 mg, Aliskiren/valsartan 300/320 mg
- Where
- 11 sites in United States, Belgium and 9 more
- Volunteers
- 1,101 people
- Sponsor
- Novartis
Myocardial Infarction
Postoperative Acute Myocardial Ischemic Injury
The investigators propose to estimate the sensitivity and specificity of the VectraplexECG System for detecting acute myocardial ischemic injury, including acute myocardial infarctions after major non-cardiac surgery.
- Trial name
- NCT02993263
- Testing
- VectraplexECG System with CEB®
- Where
- United States
- Volunteers
- 323 people
- Sponsor
- The Cleveland Clinic
Myocardial Infarction
Safety and Efficacy Study of Adjunctive Antiplatelet Therapy Prior to Primary PCI in Patients With STEMI
Safety and efficacy of adjunctive antiplatelet therapy prior to primary percutaneous intervention (PCI) in patients with ST-Elevation Myocardial Infarction (STEMI)
- Trial name
- ERASE-MI (NCT00546260)
- Testing
- PRT060128 Potassium
- Where
- 31 sites in United States, Canada
- Volunteers
- 70 people
- Sponsor
- Alexion Pharmaceuticals, Inc.